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ABSTRACT  
Buclizine is an antihistamine that is used to treat motions sickness, especially to prevent and treat symptoms such as abdomi nal pain, dizziness, 
nausea, vomiting, headaches, etc. It may also be used either alone or in a combination with other medicines for the treatment of hay fever and 
other allergic conditions. These dosages form make close contact with buccal mucosa, avoid first- pass metabolism, increase absorption and 
patient compliance, results in an enhanced drug bioavailability. Buccal adhesive tablets were prepared by direct compression.  Carbopol 940 
and Sodium Alginate was used in different ratios and also in combination. Formulated 10 batches were evaluated for physical parameter, 
swelling studies, bioadhesion studies, and in-vitro drug release and in-vitro drug permeation. Bioadhesion studies were carried out to 
determine mucoadhesive potential of prepared tablets. Tablets were evaluated for in-vitro drug release for 6 hrs, using USP type II method and. 
From these results it can be concluded that formulation batch F6 was most promising comprising of 1:4 ratio of Sodium Alginate. The best fit 
model for the optimized batch F6 was zero order having R value 0.9889 and K value is 0.2542. 
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Amongst the various routes of drug delivery, oral route is 
perhaps the most preferred to the patient and the clinician 
alike. However, per oral administration of drugs has 
disadvantages such as hepatic first pass metabolism and 
enzymatic degradation within the GI tract, that prohibit oral 
administration of certain classes of drugs especially peptides 
and proteins. Consequently, other absorptive mucosa is 
considered as potential sites for drug administration [1,2]. 
Transmucosal routes of drug delivery (i.e., the mucosal 
linings of the nasal, rectal, vaginal, ocular, and oral cavity) 
offer distinct advantages over per oral administration for 
systemic drug delivery [3,4]. These advantages include 
possible bypass of first pass effect, avoidance of presystemic 
elimination within the GI tract, and, depending on the 
particular drug, a better enzymatic flora for drug absorption. 
The nasal cavity as a site for systemic drug delivery has been 
investigated by many research groups. However, the 
potential irritation and the irreversible damage to the biliary 
action of the nasal cavity from chronic application of nasal 
dosage forms, as well as the large intra- and inter-subject 
variability in mucus secretion in the nasal mucosa, could 
significantly affect drug absorption from this site [5,6]. The 
objective of present work was to design mucoadhesive 
buccal drug delivery system in the form of buccal tablet by 
using different bioadhesive polymers like carbopol 940, 
sodium alginate which are not used individually or in 
combination with Buclizine, that could be applied to buccal 
mucosa to release the drug in buccal cavity and to increase 
the bio-availability of the Buclizine by decreasing the 
metabolism in GIT and liver, try to reduce dosing frequency 
and to improve patient compliance. 
MATERIALS AND METHODS 
Buclizine was obtained as gift sample by Mankind Pharma 
Ltd.Mumbai. India. Carbopol 940 P and Sodium alginate was 
obtained as a gift sample from S.D.Fine Chem Ltd., Mumbai. 
All other materials and solvents used were of analytical 
grade. 
Experimental Formulation of Buccoadhesive Tablets of 
Buclizine:  
All the ingredients are weigh accurately and passed through 
the sieve no. 100. Then all the ingredients were mixed 
according to decreasing order of their weight. The 
buccoadhesive tablets were prepared by using Carbopol 940, 
Sodium alginate at 1:2, 1:4, 1: 6 and 1:8 and in combination 
1:1, 1:2 drug: polymer ratio were prepared. The 
buccoadhesive tablets were prepared with selected 
polymers by direct compression on 8 station tablet 
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compression machine using 7 mm punch. Accurately 
weighed quantities of drug and other ingredients viz. 
polymers such as CP 940P, Sodium alginate, Lactose, Talc 
and Magnesium stearate, Sodium saccharine were mixed by 
triturating in a glass mortar-pestle. The blend was directly 
compressed at weight of 120 mg using flat-faced 7 mm 
diameter punch. The compositions of the formulation 
batches containing different polymers in various ratios are 
specified in table no.1. 
 Micromeritics evaluation of powder blends 
 The micromeritic evaluation of the powder blends was done 
by calculating angle of repose, bulk density, tapped density, 
and Carr’s index (% compressibility), Hausner’s ratio. 
 Evaluation of buccoadhesive tablets of Buclizine  
Thickness 
 The thickness of the tablets was determined using a 
micrometer screw gauge. Five tablets from each formulation 
were evaluated and average values were calculated [9].  
Hardness 
 For each type of formulation, the hardness value of 3 tablets 
was determined using Monsanto hardness tester [10]. 
 Weight variation test 
 For weight variation, 20 tablets of each type of formulation 
were weighed individually on an electronic balance, average 
weight was calculated and individual tablet weight was then 
compared with the average value to find out the deviation in 
weight. The % weight variation also calculates [11]. 
 Uniformity content 
 Standard solution  
Weigh accurately about 10 mg of Buclizine standard and 
transfer it into a 100 ml volumetric flask. Then add 70 ml of 
ethanol & dissolved it by mechanical shaking then Volume 
was made upto 100 ml with ethanol. The solution was 
filtered through whatman filter paper. First few ml of the 
filtrate was discarded. 5ml of the filtrate was diluted to 20 
ml with ethanol so as to get final concentration of 25 µg/ml 
[12]. 
 Test solution  
Content uniformity was determined by placing one tablet in 
a 100 ml volumetric flask. Then add 70 ml of ethanol & 
dissolved it by mechanical shaking then volume was made 
up to 100 ml with ethanol. The solution was filtered through 
Whatman filter paper. First few ml of the filtrate was 
discarded. 5ml of the filtrate was diluted to 20 ml with 
ethanol so as to get final concentration of 25 µg/ml. The 
absorbance of the resulting solution was recorded at 238 
nm. 
 Surface pH of the tablet 
 The surface pH of the tablet is measure by placing tablet 
into the distilled water for 2 hrs in the petri plate and after 2 
hr tablet was removes from the distilled water and surface 
pH of tablet measure by pH paper [13,14]. 
 In- vitro swelling index studies 
 The swelling rate of buccoadhesive tablets was determined 
using a phosphate buffer pH 6.8. The tablets were weighed 
individually and placed separately in watch glass containing 
4 ml of phosphate buffer pH 6.8. At regular intervals (30 min, 
1, 2 and 6 hours) the tablets were removed from the watch 
glass and excess surface water was removed using the filter 
paper. The swollen tablets were then reweighed and 
swelling index (SI) was calculated using following formula 
[15].                                      SI= W2-W1 x 100 
          W1 
 Where, W1 -------------- Initial weight of tablet 
               W2 -------------- Weight of swollen tablet. 
Ex-Vivo mucoadhesion time  
The Ex-vivo Mucoadhesion time is examine after application 
of buccal tablet on freshly cut sheep buccal mucosa. The 
fresh buccal mucosa is tied on the glass slide and tablet 
wetted with one drop of pH 6.8 phosphate buffers and 
pasted to mucosa by applying a light force with fingertip. 
Then the slide is put in beaker containing 200 ml of 
phosphate buffer and keep at 37±10C after 2 minute a slow 
stirring is apply to stimulate buccal cavity environment and 
tablet adhesion is record for 12 hrs. The time require for 
detaching tablet from buccal mucosa is record as a 
mucoadhesion time [16]. 
 Measurement of adhesion force 
 Gout buccal mucosa was used as the model membrane. It 
was obtained from slaughterhouse. The underlying buccal 
tissues were separated and washed thoroughly with 
phosphate buffer solution pH 6.8. It was then tied to the 
lower side of glass vial using thread. The tablet to be tasted 
was stuck on the mucosal surface. It was kept undisturbed 
for 3 minutes. Then the weights on right side of pan were 
slowly added in an increment of 0.2 gm till the tablet just 
separated from the membrane surface. The excess weight on 
the right pan i.e. total weight minus 2 gm was taken as 
measure of the bioadhesive strength. Bioadhesive force was 
calculated by using following equation [17]. Bioadhesive 
force (N) = Bioadhesive Strength  9.81 
                                                    100 
 In-vitro drug release studies 
 Standard USP dissolution apparatus was used to study the 
in-vitro release profiles using rotating paddle method. In-
vitro release study of buccoadhesive tablets of Simvastatin 
was carried out using USP type II apparatus (Paddle 
method) at 50 rpm. Each tablet was stuck at the bottom of 
flask so that drug could be released only from upper face of 
tablet. Medium used for the release rate study was 500 ml 
phosphate buffer solution pH 6.8 with 0.5 % dodecyl sodium 
sulphate. During the course of study the assembly was 
maintained at 37  0.2oC. The sample was withdrawn; 5 ml 
at time interval of 15, 30, and 45 minutes upto 6 hours and 
replaced with 5 ml of fresh dissolution method. The amount 
of Buclizine released was determined 
spectrophotometrically at 238 nm [18].  
In vitro drug permeation  
The in vitro buccal drug permeation study of Buclizine 
through the sheep buccal mucosa was performed using 
Keshary-Chien type glass diffusion cell at 37-C ± 0.2-C. Fresh 
Porcine buccal mucosa was mounted between the donor and 
receptor compartments. The buccal tablet was placed on to 
the mucosa and the compartments clamped together. The 
donor compartment was filled with 1 mL of phosphate 
buffer pH 6.8. The receptor compartment (15-mL capacity) 
was filled with phosphate buffer pH 6.8, and the 
hydrodynamics in the receptor compartment was 
maintained by stirring with a magnetic bead at 50 rpm. A 1- 
mL sample was withdrawn at predetermined time intervals 
and analyzed for drug content at 238 nm using an UV 
Spectrophotometer [19]. 
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 FTIR studies 
 The infrared spectrum of pure Buclizine was recorded and 
spectral analysis was done. The dry sample of the drug was 
thoroughly mixed with potassium bromide and directly 
placed in the sample holder. The drug-excipients interaction 
study was carried out by using FTIR to determine the 
molecular interaction between polymer and drug. All 
physical mixtures and drug sample were mixed with dried 
KBR in ratio 1:100. Then small fraction of mixture was 
compressed on automatic IR Press (Kimaya Engg. Thane, 
India) at pressure 10 tones to form transparent pellet. Then 
the IR spectrum of pellet was taken on FTIR 
spectrophotometer (Schimadzu, 8400S, Japan) [20, 21].  
Kinetic modeling 
 To analyze the mechanism of release and release rate 
kinetics of the dosage form, the data obtained were fitted 
into Zero order, First order, Higuchi matrix, Peppas and 
Hixson Crowell model using PCP-DISSO – v2 software 
[22,23]. 
 Accelerated Stability Studies 
 Accelerated stability testing of prepared formulation batch 
was carried out to determine the stability of drug and carrier 
and also to determine the physical stability of formulation 
under accelerated storage condition at various temperatures 
[24,25]. The prepared tablets were placed in borosilicate 
screw capped glass containers. The samples were kept at 
condition of 45°C+2 0 C /70% +5RH and were analyzed at 
60th , 120th and 180 days for their changes in drug content. 
 RESULT AND DISCUSSION 
 The FT-IR spectra of the pure Buclizine and physical 
mixture of drug and polymers were recorded to check 
interaction between drug and polymers. The characteristic 
peaks of Buclizine were appeared in the spectra without any 
remarkable change in the position. This indicated that there 
was no chemical interaction between Buclizine and 
polymers. The bulk density obtained for all the formulations 
in the range of 0.528 – 0.739 and the true density in the 
range of 0.650 – 0.913. The Angle of repose of the powder 
blend of all the formulations were found to be in range of 
27.56-30.500 which is in the good or in the acceptable range 
means showing the good flowability necessary for proper 
flow of powder blend into the die cavity. The Carr’s index of 
the powder blend of all the formulations were found to be in 
the range of 18.72 – 21.91 which is good or in the acceptable 
range means they shows good or fair flowability for proper 
flow of powder blend. The hausner’s ratio was found to be in 
the range of 1.13 – 1.28.Results was shown n table no.2. All 
tablet shows permissible properties Diameter of all tablets 
were found to be 8.220.02 mm. The hardness of tablets was 
found to be 3.5 to 4.24kg/cm2 . It was found that hardness 
was increased with increase in the proportion of polymers. 
The lowest hardness was obtained in formulations 
containing sodium alginate. Thicknesses of tablets were 
found to be in the range of 3.30-4.20 mm Formulations 
containing Carbopol were found to be thicker than other 
formulations as the Carbopol is fluffy in nature. All the 
tablets shows % friability in the range of 0.70-0.90 % which 
is within the limit. All the formulations pass the Weight 
variation test as all tablets within the range limit for weight 
variation. The surface pH of the tablets was found to be in 
the range of 5 - 7. All the formulations complies the test for 
Uniformity of content as it found to be within the limit of 
85%-115%. The bioadhesion and drug release profile are 
dependent upon swelling behavior of the tablets. Swelling 
index was calculated with respect to time. Swelling index 
increased as the weight gain by the tablets increased 
proportionally with the rate of hydration. From the results 
shown in Figure no. 7 it is conclude that appropriate 
swelling behavior of the buccal adhesive system is an 
essential property for uniform release of drug and effective 
mucoadhesion. The rate and extent of swelling increased 
with an increasing concentration of polymer in the 
formulation. The maximum swelling index was observed in 
formulations containing Carbopol 940 as it is hydrophilic in 
nature and absorbs solution rapidly. The maximum swelling 
was attained at the 4 to 5 hrs after that tablet starts to erode 
slowly. The Sodium Alginate also absorbs solution but shows 
low swelling index than Carbopol 940. From the results 
shown in Fig.no.8 it is conclude that the bioadhesion 
characteristics were found to be affected by the nature and 
proportion of the bioadhesive polymers used. The maximum 
Bioadhesive force was observed in the formulations, F1 to 
F4, which contains Carbopol 940 in four different ratios, 
Bioadhesive force was found to increase with increase in 
proportion of Carbopol 940.The reason for such high 
bioadhesion force of Carbopol 940 might be ionization of 
Carbopol 940 at salivary pH which leads to improved 
attachment of the tablet to mucosal surface. The formulation 
F5 to F8 containing Sodium Alginate in four different ratios 
shows bioadhesive force less than Carbopol 940.The 
bioadhesive force is increasing in these formulations as the 
polymer concentration increases as observed in case of 
Carbopol 940..The Mucoadhesion time were found to 
increase with the increase in polymer concentration The 
mucoadhesion time in formulations containing Sodium 
Alginate was found to be lower than formulation containing 
Carbopol 940. The formulation F1 containing carbopol in 1:2 
ratios gives the greater release than F1, F2 and F3 because of 
lower concentration of carbopol. As the concentration of 
Carbopol 940 increase in the formulations causes a slower 
release profile this finding may be due to the stronger 
binding and cohesion force between the particles. Due to this 
the drug release get slower and did not released within 6 
hrs. In this finding the formulations containing sodium 
alginate gives the better release of drug as compare to 
formulations containing carbopol.In the formulations F5 to 
F8 the F6 gives the highest release of drug than formulations 
F5,F7 and F8 which contains the sodium alginate in 1:4 ratio. 
Whereas the formulation F8 gives the lower release of the 
drug as compare to formulations F5, F6, F7 which contains 
the sodium alginate in 1:8 ratio The results of dissolution 
studies indicated that the release was varied according to 
the type and ratio of the polymer used. Formulation batch F6 
containing sodium alginate in 1:4 ratio has shown maximum 
percent of drug release 88.79 % over the period of 6 hrs, of 
Simvastatin buccal tablet. The optimized batch F6 was 
studied for in-vitro permeation study. The results showed 
that 80.10% drug was permeated in 6 hrs. The in vitro 
release data was applied to various kinetic models to predict 
the drug release kinetic mechanism shown in table no.22. 
The best fit model for the optimized batch F6 is zero order 
having R value 0.9889 and K value is 0.2542. The stability 
studies of the buccoadhesive tablets revealed that no 
significant changes in the physical parameters when stored 
at storage temperature of 45 0C and at room temperature. 
No significant reduction in the content of the active drug was 
observed over a period of 180 Days hence shelf life of the 
formulation could extrapolate to a minimum of two years.
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Table 1. Composition of Buclizine buccoadhesive tablets 
Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Buclizine 10 10 10 10 10 10 10 10 10 10 
Carbopol 940 20 40 60 80 -- -- -- -- 10 20 
Sodium Alginate -- -- -- -- 20 40 60 80 10 20 
Sod. Saccharine 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
Lactose 85.8 65.8 45.8 25.8 85.8 65.8 45.8 25.8 85.8 65.8 
Mag. Stearate 2 2 2 2 2 2 2 2 2 2 
Talc 2 2 2 2 2 2 2 2 2 2 
Total wt. 120 120 120 120 120 120 120 120 120 120 
 
Table 2. Physical parameters of buccoadhesive tablets 






Carr’s Index Hausner’s Ratio 
F1 0.687± 0.04 0.855±0.02 29.25 19.64 1.28 
F2 0.677±0.03 0.863±0.03 30.50 21.49 1.27 
F3 0.660±0.05 0.838±0.05 29.25 21.24 1..26 
F4 0.739±0.04 0.913±0.06 30.25 19.07 1.23 
F5 0.659±0.05 0.844±0.02 27.56 21.91 1.28 
F6 0.620±0.03 0.783±0.04 29.25 20.71 1.26 
F7 0.576±0.04 0.713±0.04 29.21 19.25 1.13 
F8 0.528±0.03 0.650±0.04 30.25 18.72 1.23 
F9 0.650±0.04 0.835±0.04 29.15 18.60 1.14 
F10 0.655±0.05 0.840±0.05 30.40 19.15 1.20 
 
Table 3. Physical parameters of formulation batches of buccoadhesive tablets 
Formulations Hardness 
(kg/cm2)* (± SD) 
Thickness 
(mm)* (± SD) 








F1 3.5 ± 0.163 3.51±0.028 0.75 121.4 - 4.40 -3.00 6-7 97.33± 1.46 
F2 3.6 ± 0.163 3.71±0.028 0.75 120.6 - 3.81 -4.41 6-7 99.29±2.45 
F3 3.8 ± 0.115 3.80 ± 0.05 0.70 120.7 -3.02 -3.60 6-7 100.46±2.95 
F4 4.4 ± 0.191 4.20±0.036 0.75 120.9 - 4.09 -4.17 6-7 98.26±1.24 
F5 3.4 ± 0.081 3.60±0.011 0.80 119.8 - 3.17 -2.67 5-6 99.26±2.45 
F6 3.6 ±0.125 3.56 ± 0.05 0.90 120.9 - 2.43 -3.44 5-6 98.26±1.20 
F7 3.9 ±0.163 3.44±0.026 0.85 119.4 - 4.52 -2.17 6-7 101.23±2.19 
F8 4.1 ± 0.191 3.30 0.028 0.70 120.9 - 4.09 -3.34 5-6 99.25±2.46 
F9 3.4 ± 0.081 4.20±0.036 0.85 120.9 - 2.43 -3.44 5-6 99.26±2.45 
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Table 4. Effect of polymers on bioadhesive strength, bioadhesive force and mucoadhesion time of formulation batches 
of buccoadhesive tablets 
Formulations Bioadhesive Strength (gm)*(± SD) Bioadhesive Force(N)* (± SD) Mucoadhesion Time (Hr)* (± SD) 
F1 6.8 ± 1.3 0.667 0.127 120.50 
F2 9.3 ± 1.5 0.9120.147 140.65 
F3 15.4 ± 1.45 1.5100.142 170.60 
F4 20.6 ± 1.55 2.0200.152 200.46 
F5 4.8 ± 1.4 0.4700.137 90.34 
F6 6.5 ± 1.1 0.6370.107 110.41 
F7 8.8 ± 1.25 0.8630.117 120.36 
F8 11.4 ± 1 1.1180.098 150.21 
F9 6.6 ± 1.4 0.665 0.126 110.45 
F10 4.6 ± 1.3 0.4500.137 100.38 
 
Table 5. Kinetic modeling 
Formulations Best Fit Model R K 
F1 Peppas 0.9897 3.0037 
F2 Peppas 0.9809 1.5301 
F3 Peppas 0.9905 0.8732 
F4 Peppas 0.9975 0.9252 
F5 Hix.Crow. 0.9944 -0.0010 
F6 Zero Order 0.9889 0.2542 
F7 Zero Order 0.9945 0.2350 
F8 Hix.Crow. 0.9964 -0.0011 
F9 Peppas 0.9797 3.0027 
F10 Peppas 0.9809 1.4023 
 
Table 6. Accelerated Stability studies for optimized batch F6 
Parameters Initial 60 Days 120 Days 180 Days 
Colour White No Change No Change No Change 
Hardness(kg/cm2) 3.6 ±0.125 3.6 ± 0.081 3.6 ±0.056 3.5 ± 0.163 
Drug Uniformity (%) 98.26±1.20 98.24 ±1.15 98.22 ±1.05 97.21± 1.02 
% DrugRelease 88.79 88.15 87.50 87.05 
 
 
Figure 1. FT-IR spectrum of Buclizine 
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Figure 2. FT-IR spectrum of carbopol 940 
 
Figure 3. FT-IR spectrum of sodium alginate 
 
Figure 4. FT-IR spectrum of Buclizine with carbopol 940. 
 
Figure 5. FT-IR spectrum of Buclizine with sodium alginate. 
 
Figure 6. FT-IR spectrum of Buclizine with carbopol & sodium alginate 
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CONCLUSION 
 The results of the present study indicate that buccal tablets 
of Buclizine with controlled drug release can be successfully 
prepared by direct compression method using Carbopol 940 
and Sodium Alginate as mucoadhesive polymers The 
formulation F6 the drug matrix composition 1:4 ratio of 
Sodium Alginate was found to be promising, which shows an 
in vitro drug release of 88.79 % in 6hrs along with 
satisfactory bioadhesion strength (6.5 ± 1.1g). The in vitro 
release kinetics studies reveal that the best fit model for the 
optimized batch F6 is zero order having R value 0.9889 and 
K value is 0.2542. So buccal tablet of Buclizine were 
encouraging, and it need for further study for 
reproducibility. Therefore Buclizine can be given by this 
route for better availability and can be minimized side 
effects of drugs. 
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